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Dendritic cells (DCs) are a heterogeneous group of mononuclear phagocytes with versatile
roles in immunity. They are classified predominantly based on phenotypic and functional
properties, namely their stellate morphology, expression of the integrin CD11c, and major
histocompatibility class II molecules, as well as their superior capacity to migrate to
secondary lymphoid organs and stimulate naïve T cells. However, these attributes are
not exclusive to DCs and often change within inflammatory or infectious environments.
This led to debates over cell identification and questioned even the mere existence of
DCs as distinct leukocyte lineage. Here, we review experimental approaches taken to fate
map DCs and discuss how these have shaped our understanding of DC ontogeny and
lineage affiliation. Considering the ontogenetic properties of DCs will help to overcome
the inherent shortcomings of purely phenotypic- and function-based approaches to cell
definition and will yield a more robust way of DC classification.
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Introduction
Dendritic cells (DCs) were originally identified in mouse spleen for their unique stellate mor-
phology, their ability to adhere to certain glass surfaces and their superior capacity to activate
naïve T lymphocytes that distinguished them frommacrophages (MØs) (1–3). Mostly for historical
reasons, DCs are considered part of the mononuclear phagocyte (MP) system, which groups all
highly phagocytic cells derived from monocytes or their precursors based on the premise that
tissue MØs arise from monocytes (4–9). This presumed relatedness of DCs, monocytes, and MØs
coupled to the lack of reliable ways to distinguish MP subtypes has caused continuous debates over
accurate cell-type identification and has led some to question whether DCs in fact constitute an
independent cell lineage (6, 7, 10–14). However, today we have conclusive evidence demonstrating
that DCs,monocytes, andMØs have distinct cellular origin andwe further distinguish plasmacytoid
DCs (pDCs) from two subsets of so-called conventional or classical DCs (cDCs) based on unique
developmental requirements (7, 15–19). Nonetheless, DCs remain defined based on phenotypic and
functional properties that often overlap with those of monocytes or MØs (19), although some have
suggested a shift in paradigm toward a nomenclature that takes cell ontogeny into account (6, 7, 10).
Dendritic cells are generally identified by their high expression of major histocompatibility
complex class II molecules (MHCII) and of the integrin CD11c, as well as their superior capacity
to migrate from non-lymphoid to lymphoid organs and stimulate naïve T cells (3, 20–22). However,
these characteristics are not absolute and can change in situations of inflammation or infection, thus
complicating cell identification (6, 7, 23, 24). For instance, CD11c, considered the hallmark surface
marker of DCs, is also found on B, T, and NK cells as well as somemonocytes, MØs, and eosinophils
(25–32). Dendritic protrusions have also been observed in some MØs and T cells (33–35). Further,
surface markers, such as F4/80, CD14, or CD64 (Fc-gamma receptor 1), generally associated with
monocytes orMØs can be found onDCs (36–38). Onemight argue that themost defining feature of
DCs is their ability to activate T cells, however such definition discounts the fact that DCs potently
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regulate innate immune responses independent of their ability to
migrate to lymphoid organs or stimulate T cells (39–44). Con-
versely, non-DCs can carry antigen to lymph nodes and activate
naïve T cells in some instances (45–47).
Therefore, morphological and functional properties, as well
as the expression of surface markers are insufficient to clearly
distinguish DCs from monocytes and MØs, raising the necessity
to find a more robust way of cell identification. Recent studies in
mouse and human indicate that DCs, MØs, and monocytes have
unique ontogenetic properties and thus can be considered distinct
cell lineages (36, 48–54). Here, we review approaches that have
been employed to track and define the progeny of DC precursors
in vivo and discuss how such “fate mapping” approaches have
improved our understanding of DC heterogeneity and ontogeny.
These studies lay the foundation for moving toward cell ontogeny
as a major lineage-determining criterion, which will allow for a
more reliable and precise classification of DCs and DC subsets.
DC Development
Dendritic cells are short-lived and their maintenance relies on
constant replenishment from bone marrow progenitors that orig-
inate from hematopoietic stem cells (HSCs) (19, 55). In the classic
model of DC development monocytes and DCs arise from bi-
potent progenitors, so-called MØ and DC progenitors (MDPs)
(Figure 1) (56). MDPs further give rise to common DC pro-
genitors (CDPs) restricted to the generation of pDCs and cDCs












FIGURE 1 | Classic model of DC development. DCs and monocytes are
ancestrally related and arise from bi-potential MDPs residing in the bone
marrow. MDPs further differentiate into monocytes and CDPs, which are
restricted to the generation of various types of DCs. CDPs give rise to pDCs,
which fully develop in the bone marrow, and pre-DCs, which migrate through
the blood to tissues, where they fully differentiate into CD11b  (including
CD8α+ cDCs in lymphoid tissue and migratory CD103+ cDCs in
non-lymphoid tissue) and CD11b+ cDCs. Monocytes complete their
development in the bone marrow and reach peripheral tissues via the
bloodstream. There they further differentiate into monocyte-derived DCs
(mo-DCs) or MØs (mo-MØs) in response to environmental cues.
marrow, thus exit the bone marrow as fully developed cells
and reach peripheral organs via the blood stream (Figure 1)
(15, 59). In contrast, cDCs arise from another developmen-
tal intermediate termed pre-DC, which exits the bone marrow
and migrates through the blood to seed lymphoid and non-
lymphoid tissues (60, 61). There, pre-DCs terminally differentiate
into cDCs, including the main CD11b  and CD11b+ subtypes
(Figure 1) (60–63). In lymphoid tissues these areCD8α+CD11b 
and CD11b+ resident cDCs, whereas in non-lymphoid tissues
they comprise CD103+CD11b  and CD11b+ migratory cDCs
(3, 60–63). Like pDCs, monocytes complete their development
in the bone marrow but in tissues they differentiate into cells
with DC- or MØ-like features (Figure 1) (23, 24, 64, 65). This
plasticity is remarkably prominent in inflammatory or infectious
environments, whenmonocyte-derived cells with qualities of DCs
have been referred to as TNF-α/iNOS-producing DCs (Tip-DCs),
monocyte-derived DCs (mo-DCs), and/or inflammatory DCs
(23, 24, 64, 65).
Although most of our knowledge concerning DC development
is derived from mouse studies, developmental parallels have been
observed in other species (66–73). Especially the identification of
putative equivalent DC progenitor populations in human holds
promise for future research (72, 73). Yet, some uncertainties
remain. Common lymphoid progenitors (CLPs) can give rise
to DC descendants upon adoptive transfer (74), although it is
now thought that DCs originate predominantly from myeloid
progenitors (75, 76). Nonetheless, some pDCs, but not cDCs,
show evidence of VDJ gene rearrangements, potentially indicat-
ing lymphoid lineage heritage (15, 59, 77). However, it remains
unclear whether evidence of Rag gene expression history neces-
sarily means that pDCs have dual lymphoid and myeloid origin.
Contrary to the dogma that monocytes and DCs share a common
immediate ancestor, recent data suggest that lineage divergence
of HSC-derived myeloid cells occurs much earlier than previously
predicted and that monocytes and DCs might arise independent
of a bi-potential developmental intermediate (49, 78, 79). Eluci-
dating such unresolved aspects pertaining to DC ontogeny may
solve uncertainties in determining lineage affiliation, which, in
turn, will aid to further decipher the unique functions of DCs in
immunity.
Fate Mapping
Understanding cell development requires models with which the
relationship of a precursor cell and its progeny can be defined
in vivo. Such “fate mapping” can be achieved in various ways and
relies on the selective labeling of the cell(s) of interest so that con-
sequently the development of themarked cell can be followed in its
natural environment (80). Tracing progenitors in vivo also offers
the possibility to determine the fate of populations when lineage
affiliation is most heavily debated, namely following experimental
manipulation to generate conditions of inflammation or infection.
While most fate mapping strategies follow the progeny of bulk cell
populations, recently developed techniques have enabled the trac-
ing of single cells, thus providing valuable information regarding
their developmental potential at the clonal level (80, 81). In all
fate mapping experiments, it is important to consider that their
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interpretation is dependent on the use of select, faithful and stable
markers (82).
Precursor Transfers
The transfer of purified and pre-marked precursor cells into con-
genic recipients is the most accessible form of fate mapping as
a variety of labeling options can be used to distinguish between
donor and host cells (Figure 2A) (80). As a result, precursor
transfers are commonly used to study cell development and lin-
eage relationships and remain a standard protocol for defining
the stemness of progenitor cells (80). Such experiments rely on
the ability to purify sufficient precursors that, after cell isolation,
retain the capacity to home to the appropriate anatomical niche
and expand sufficiently into detectable progeny. To circumvent
such limitations transfer studies are often combined with proto-
cols to induce leukopenia, such as irradiation, in order to increase
the niche available for cell engraftment (Figure 2A) (80). How-
ever, these manipulations can alter developmental signals, which,
in turn, might impact on the interpretation of results (18, 54, 83).
To best mimic the endogenous cellular environment, progenitors
have been returned directly to their organs of origin, for instance
by intra-bone injection (84).
The DC progenitors MDP, CDP, and pre-DC were in part
defined by assessing their developmental potential after adoptive
transfer into mice (56–58, 60, 61, 84–86). In such experiments,
MDPs give rise to DCs and monocytes, whereas CDPs and pre-
DCs are restricted to the generation of DCs but do not gener-
ate monocytes or other leukocyte lineages (56–58, 61, 84–86).
In combination with experiments assessing the differentiation
potential of single progenitors in vitro (56–58), these studies have
significantly shaped our view of DC development (Figure 1).
Surprisingly, the existence of MDP as a bi-potential intermedi-
ate for DCs and monocytes has recently been questioned when
single CX3CR1+ MDPs were unable to generate both DCs and
monocytes upon differentiation in vitro (78). The authors further
found that adoptively transferred CX3CR1+MDPs, not only gave
rise to DCs and monocytes but also neutrophils (78). However,
such multi-potency of MDPs was not observed in earlier studies
(52, 56, 61, 85, 86) and is not evident in genetic CX3CR1 fate
mapping experiments (50). It is possible that these discrepancies
may be explained by experimental variation such as differences
in cell isolation, the timing of analysis or variances in the niche
available for cell engraftment following irradiation (18, 54, 83). In
light of these results it is noteworthy, however, that upon adoptive
transfer MDPs exhibit pDC potential only in some studies (52,
86) but not others (56, 85), whereas the presumed downstream
CDPs produce both pDCs and cDCs (57, 58). Taken together
these experiments raise some doubt about the existence of a MDP
as a key developmental intermediate for monocytes, cDCs, and
pDCs. However, resolving this matter will require the use of
better models to trace single cells in vivo as experiments relying
on the isolation and analysis of bulk progenitor populations are
inherently prone to disparities in gating strategy or cell purity.
In DC ontogeny, these issues are augmented because MDP and
CDP exhibit substantial phenotypic overlap: both lack lineage-
defining markers, are characterized by expression of CX3CR1,
CD115 (M-CSFR, Csf1R) as well as CD135 (FMS-like tyrosine
kinase 3, FLT3) and, until recently, CDP could only be distin-
guished from MDP by lower expression of the receptor tyro-
sine kinase CD117 (c-kit) (56–58, 61, 86). We have recently
found that the C-type lectin receptor DNGR-1 (Clec9a) marks
cells resembling CDPs (36). Surprisingly, upon adoptive transfer,
DNGR-1+CD115+ progenitors exhibit cDC-restricted differen-
tiation potential and do not generate pDCs (36), suggesting
that DNGR-1 marks cDC-restricted progenitors. These data are
in line with a recent study demonstrating a strong bias for
CD115+ CDPs to generate cDCs, whereas pDCs arise predom-
inantly from CD115 negative cells (79). Therefore, cDCs and
pDCs appear to have distinct developmental intermediates that
can be distinguished by expression of CD115 (79) and DNGR-1
(36). Since CD115+ CDPs presumably express DNGR-1 (36),
it is unclear why some CD115+ CDPs show combined cDC
and pDC potential in clonal assays (57, 58, 79). It is possi-
ble that antibody-mediated triggering of DNGR-1 or growth
factor receptors, such as CD115, during cell isolation skews
DC differentiation toward a particular DC sub-lineage in an
unforeseeable manner. The developmental potential of progen-
itors may also be influenced by the specific culture conditions
used (78) or DCs could exhibit a degree of developmental plas-
ticity (87). Nonetheless, the existence of a putative intermedi-
ate monocyte-restricted progenitor downstream of MDP (com-
mon monocyte progenitor, cMoP) (52) alongside the aforemen-
tioned pDC- and cDC-restricted progenitors supports a model
in which monocytes, cDCs, and pDCs develop independently.
The genuine point of lineage divergence, however, remains to be
determined.
Questions regarding the lineage affiliation of DCs have been
muddled significantly by the developmental plasticity of mono-
cytes (6, 24). The phenotypic transformation of monocytes into
DC-like cells is most prominent in inflamed environments (8, 19,
23, 24). It can also be mimicked in vitro by culturing monocytes
in the presence of GM-CSF (granulocyte-macrophage colony-
stimulating factor) IL-4 (Interleukin-4) (88, 89). However,
in vivo the inflammation-induced differentiation of monocytes
into cells with attributes of DCs appears GM-CSF-independent
(90), highlighting that the developmental requirements underly-
ing this phenotypic conversion in vitro might differ from those
involved in vivo. In the absence of experimentally induced infec-
tion or inflammation, adoptively transferred monocytes readily
acquire CD11c and MHCII expression as well as functional fea-
tures of DCs in non-lymphoid tissues (91–95). This phenotypic
conversion is also observed after adoptive transfer into unir-
radiated hosts, which most closely mimics steady-state condi-
tions (63). In contrast, transferred monocytes do not generate
DCs in lymphoid organs, even if the niche for engraftment is
opened by depletion of CD11c+ cells (84). Importantly, in non-
lymphoid tissues monocytes exclusively generate CD11b+, but
not CD103+CD11b  cells, which is in contrast to CDPs and pre-
DCs that generate CD11b+ as well as CD103+CD11b  cDCs
(63, 91–95). Therefore, CD11c+MHCII+CD11b+ cells in non-
lymphoid tissues appear to constitute a population of mixed cellu-
lar origin that can arise frommonocytic progenitors as well as pre-
DCs. Adoptive transfer experiments do not allow to determine
the relative contribution of each progenitor to this population,
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FIGURE 2 | Strategies to fate map DCs.
(Continued)
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 1994
Poltorak and Schraml Fate mapping of dendritic cells
FIGURE 2 | Continued
(A) Progenitors are adoptively transferred to assess their differentiation in the
physiological context. Graft-derived cells are distinguished from host cells based
on pre-defined labels, for instance congenic markers. This method is often
combined with strategies to increase the niche available for cell engraftment,
such as irradiation. (B) In transgenic approaches, lineage-restricted promoters
can be used to drive a reporter gene. Target cell populations can be visualized
by the expression of fluorescent proteins or can be depleted. In the latter case,
cell-restricted expression of DTR allows for conditional cell ablation following DT
injection. (C) Progenitors are transduced in vitro with semi-random DNA
sequences (barcodes) by retro- or lentiviral vectors and subsequently
transferred into irradiated congenic recipients. After differentiation, cell progeny
are analyzed for their barcode repertoire using deep sequencing or microarray.
The representation of a given barcode in multiple cell populations indicates
multi-potency of the transferred cell. (D) Expression of Cre recombinase is
driven by a lineage or cell-specific promoter. Additionally, a reporter gene,
usually a fluorescent protein, is placed under control of a constitutive promoter.
Expression of the reporter is blocked by inserting a loxP-flanked STOP cassette
(1). Cre expression leads to excision of the STOP cassette resulting in
expression of the reporter gene (2). Since the promoter-driving reporter gene
expression is constitutively active, the target cell is irreversibly labeled
irrespective of continuous Cre expression (3).
although surrogate markers such as CD64 or Mar-1 can serve
to distinguish monocyte-derived cells from bona fide pre-DC-
derived cDCs (46, 93, 94).
Notably, in irradiated hosts transferred monocytes can also
generate CD11c+MHCII+ cells of the epidermis, which resemble
Langerhans cells (LCs) (96–99). LCs exhibit many phenotypic and
functional features of DCs, such as the capacity to migrate to
lymphoid organs and stimulate naïve T cells, and have long been
considered a prototypical DC population (96–99). However, we
now realize that the majority of LCs is established before birth
and maintained under steady-state conditions by self-renewal
from local progenitors (96, 97, 99–102). These properties thus
ontogenetically separate LCs from bone marrow-derived DCs or
monocyte-derived cells. Moreover, monocytes may not necessar-
ily adopt features of DCs or MØs upon entry into tissues, as a
recent study indicates that monocyte can also exist in tissues with-
out further differentiation (45). When considering this immense
plasticity it will be crucial to elucidate the environmental cues
that shape the diverse fates of monocytes to further dissect the
full functional spectrum of monocytes and monocyte-derived
cells.
Lineage Restricted Reporters
When the availability of isolatable progenitor cells is limiting and
when populations are ontogenetically heterogeneous or might
be influenced by alterations in their surroundings, determining
lineage affiliation requires models to trace cells directly in their
natural environment. One way to achieve this is by engineering
models in which lineage-restricted promoters or genetic elements
drive the expression of reporter genes (Figure 2B) (80, 82, 103).
It is important to bear in mind that such experiments assume that
the expression of the selectedmarker is restricted to the cell lineage
in question and therefore, the choice of stable and specificmarkers
is essential (80, 82, 103). Additionally, the genetic elements used to
drive expression of the reportermust faithfullymimic endogenous
gene expression (80, 82, 103).
Genetic elements of the Itgax gene, which encodes CD11c, have
extensively been used to generate reporters to studyDCs (82, 103).
As such, transgenic mice in which the CD11c promoter drives
the expression of fluorescent proteins (Figure 2B) have been key
to visualizing the distribution and cellular interactions of DCs
in a variety of tissues, including lymphoid organs, heart, lung,
and skin (103–107). But fate mapping can also be achieved by
cell deletion. Transgenic expression of primate diphtheria toxin
receptor (DTR) renders murine cells susceptible to diphtheria
toxin (DT)-induced cell death and, thus, enables inducible target
cell depletion (Figure 2B) (82, 108). In this sense mice in which
DTR expression is controlled by the elements of the CD11c pro-
moter have been widely used to characterize the in vivo functions
of DCs (28, 109–112). In part through analyzing such reporter
mice, however, it has become evident that CD11c expression is not
entirely restricted to DCs. It is also expressed on alveolar MØs,
Ly6Clow as well as activated monocytes, plasmablasts, NK cells,
and some T cells (25–29, 113). In addition, CD11c-driven fate
reporter expression varies depending on the specific promoter
elements used for transgenesis. CD11c.DTR mice, which were
generated by conventional transgenesis using a 5.5-kb promoter
element of the Itgax gene (109, 114), efficiently deplete most
CD11c-expressing cDCs, LCs, alveolar, splenic marginal zone,
and metallophilic MØs, as well as plasmablasts and T cells (27,
109, 115). However, DT-induced cell depletion in these mice
is incomplete and spares certain cell types that transcribe their
endogenous Itgax allele, including pDCs and NK cells (82, 115).
Additionally, prolonged cell depletion using CD11c.DTR mice
requires the use of bone marrow chimeras, possibly because of
aberrant DTR expression on non-immune cells (82, 108, 112).
Notably, this is not the case in CD11c.DOG and CD11c.LuciDTR
mice, which were generated using bacterial artificial chromosome
(BAC) transgenesis to place DTR under control of the extended
regulatory region of the Itgax gene and in which DTR expression
seems to more faithfully represent endogenous CD11c expression
(28, 112, 115, 116). In all models, the occurrence of systemic
neutrophilia and monocytosis following CD11c+ cell depletion
(28, 115, 117) adds another layer of complexity to deciphering the
cellular function and lineage affiliation of DCs.
The realization that CD11c is not restricted to DCs in
all instances nurtured the search for more specific lineage-
defining markers. Two groups simultaneously identified the
transcription factor Zbtb46 (zDC, Btbd4) as ideal candidate
to distinguish cDCs, as it is expressed in pre-DCs and cDCs
but not in pDCs or their precursors (37, 38). Consistently,
CD8α+ and CD11b+ cDCs in lymphoid organs as well as
CD103+ cDCs in non-lymphoid organs uniformly express
Zbtb46 as assessed in Zbtb46-GFP (37) and Zbtb46-DTR (38)
reporter mice generated by site-directed mutagenesis. In contrast,
CD11c+MHCII+CD11b+ cells in non-lymphoid organs,
including lung, small intestine, and kidney, exhibit partial Zbtb46
expression (37, 38) indicating that they represent a heterogeneous
population. This is consistent with reports demonstrating that
these cells are of mixed monocyte and pre-DC origin (63, 91, 92,
95). Subsequently, Zbtb46 reporter mice have been used to help
establish lineage relationships in a variety of tissues including
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heart, pancreas, tumors, and thymus (118–121). The fact that
Zbtb46 expression is also found in human DCs suggests that it
may also help to identify DCs across species (48, 122).
Nevertheless, the use of Zbtb46 as lineage-defining marker
requires a note of caution. Zbtb46 expression is downregulated
after DC stimulation and it is found in some non-immune cells
(37, 123). Despite its prominent expression in the cDC lineage,
Zbtb46 appears largely dispensable for cDC development (37,
123). Instead, it may reinforce DC-specific transcriptional pro-
grams (37) and/or suppress DC activation (123). Interestingly,
monocytes activated in the presence of GM-CSF IL-4 uniformly
induce Zbtb46 expression, whereas monocyte-derived Tip-DCs
that are generated following infection with Listeria monocytogenes
do not (37). This raises the possibility that Zbtb46 may control
DC-like features of monocyte-derived cells in some inflamma-
tory situations and it will be interesting to determine if Zbtb46
controls transcriptional programs in monocytes. These data also
highlight that despite its selective expression on cDC progenitors




Establishing that the development and/or delineation of a cell
type depends on a certain transcription or growth factor consti-
tutes a powerful way of fate mapping that has extensively been
applied toMPs (42, 51, 63, 124–141).We can now clearly delineate
DCs into distinct subpopulations based on the transcriptional
programs that govern their development. pDCs are distinguished
from two subsets of cDCs by their dependence on E2-2 (67, 142).
The differentiation of pre-DCs into CD8α+ cDCs in lymphoid
organs and CD103+CD11b  cDCs in non-lymphoid tissues is
controlled by a set of transcription factors, including Irf8, Nfil-3,
Id2, and Batf3 (124–128). Therefore, CD8α+ cDCs and CD103+
cDCs represent a developmentally related lineage of cDCs (6, 7).
Notably, these cells also exhibit a degree of functional relatedness
that is, for instance, exemplified by their superior capacity to
activate CD8+ T cells (124, 143–145). In contrast, the develop-
ment of CD11b+ cDCs from pre-DCs is controlled by distinct
transcription factors, including RelB, RbpJ, PU.1, and Irf4 (42,
129–136). Notably, expression of CD24 separates pre-DCs into
cells that preferentially generate either CD8α+ or CD11b+ cDCs
in spleen (60) suggesting a stepwise differentiation of pre-DCs
into cDCs. It will be interesting to determine whether such het-
erogeneity of pre-DCs also exists in the bonemarrow. Notably, the
extent of transcription factor dependence is linked to the genetic
background of the particular mouse strain analyzed (146–148),
indicating that transcriptional requirements are not always abso-
lute or redundant factors exist (148). Consistently, CD8α+ DCs
candevelop in the absence of Batf3, Id2, andNfil-3 (149). The local
microenvironment may also contribute to shaping the diversity
of the DC compartment, as in some tissues, such as the spleen
and intestinal system, CD11b+ cDCs can be divided into onto-
genetically and functionally distinct subpopulations (36, 42, 91,
95, 131). Importantly, some of the transcription factors control-
ling DC differentiation in mice have also been implicated in the
development of human DCs (67, 69, 71) and putative equivalent
DC subpopulations exist in rat, chicken, sheep, and pig (150–153),
highlighting that DC populations are conserved across species.
While several growth factors have been linked to DC differen-
tiation, the development of all DC subsets is strongly dependent
on FLT3 ligand (FLT3L) and downstream signaling events (7, 18,
154). FLT3L administration potently expands pDCs and cDCs
in mice and humans (72, 73, 85, 155–157). In vitro, FLT3L pro-
motes the differentiation of bone marrow progenitors from mice,
humans, and pigs into functional subsets of DCs (66, 158, 159).
Mice lacking FLT3L display a severe deficiency in DCs, which is
also apparent, although to a lesser extent, inmice lacking its recep-
tor CD135 or mice treated with CD135 inhibitors (63, 137, 160,
161). In contrast, FLT3L appears largely dispensable for monocyte
and MØ development (137) and, therefore, FLT3L dependency is
often used delineate DCs in vivo (18, 65, 162). The interpretation
of fate mapping using mice deficient in CD135 or its ligand is
however complicated by the fact that these animals also exhibit
abnormalities in other hematopoietic lineages, including B, T, and
NK cells (137, 163) and show evidence of systemic neutrophilia
and monocytosis, as has been reported in other DC-deficient
models (112, 117).
Despite the prominent expression of CD135 onDC progenitors
it remains to be clarified exactly at what stage of cellular differ-
entiation FLT3L impacts on DC development. Consistent with a
role for FLT3L early in development, a reduction of bone marrow
CDPs in FLT3L deficient animals has been reported but ranges
from amere twofold decrease (164) to near complete absence (78).
In contrast, the numbers of MDPs and splenic pre-DCs appear
largely unaffected by CD135 deficiency (85). The observation that
pre-DC frequencies in non-lymphoid organs of FLT3L-deficient
mice are reduced (63) and that transfer of DCs into a FLT3L-
deficient environment decreases their homeostatic proliferation
(85) indicates a role for FLT3L in the peripheral expansion of
DCs rather than their differentiation. This interpretation would
equally be consistent with the observation that DCs that develop
in the absence of FLT3L are functional (137). In light of this
finding it will be interesting to determine, to what extent FLT3L
impacts on the development and functional regulation of other
MPs. Addition of FLT3L to purified human monocytes cultured
with GM-CSF IL-4 increases their T cell stimulatory capacity
(165), although it is not clear whether this is also the case for
murine monocytes. Culture of murine bone marrow with GM-
CSF and IL-4 presumably mimics monocyte differentiation under
the same conditions (166). When FLT3 signaling is inhibited in
such bulk cultures the T cell stimulatory capacity of the output
cells is reduced (161). Therefore, these data raise the possibility
that FLT3L might influence monocyte differentiation into cells
with functional properties of DCs also in the murine system,
although a direct causality remains to be demonstrated. Fur-
ther, comparative gene expression profiling revealed that upon
migration to lymph nodes LCs induce CD135 expression (167),
indicating that they might be capable of responding to FLT3L.
Therefore, it is conceivable that FLT3L may control certain func-
tional aspects generally associated with DCs, such as antigen pre-
sentation, in ontogenetically distinct MP subtypes, which will be
interesting to formally address in the context of FLT3L or CD135
deficiency.
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Dendritic cell progenitors also express CD115, the receptor for
MØ colony-stimulating factor (M-CSF) (56–58, 61, 86). However,
compared to the dominant role of FLT3L in DC differentiation,
M-CSF-deficiency onlymildly impacts onDCdevelopment (168).
M-CSF deficient osteopetrotic (op/op) mice exhibit a two- to
threefold reduction in splenic cDCs and pDCs, respectively, but
the remaining DCs are capable of stimulating amixed lymphocyte
reaction and induce costimulatory molecules upon activation,
thus appear functional (168). In contrast, M-CSF is strongly
required for monocyte and MØ development (141, 169). There-
fore, the observation that mice lacking CD115 exhibit reduced
frequencies of CD11c+MHCII+CD11b+ cells in non-lymphoid
organs (63, 91) likely reflects the ontogenetic heterogeneity of
this population (63, 91–95). Consistently, M-CSF is also required
for the generation of monocyte-derived cells with features of
DCs during inflammation (90). Nonetheless, M-CSF may play
a role in DC development. It can promote DC differentiation
in vitro and in vivo even in the absence of FLT3L, although
DCs generated by M-CSF alone phenotypically and function-
ally differ from those induced by FLT3L (170). M-CSF-induced
DC poeisis is also more efficient in FLT3L-sufficient conditions
(170). In vivo, antibody-mediated blockade of M-CSF in pregnant
mice reduces pre-DC extravasation, translating into a reduction
of CD11b+ DCs in the pregnant uterus (171). Whether M-CSF
affects pre-DC migration also in other tissues and whether it
acts in a cell intrinsic manner or by promoting the produc-
tion of chemotactic factors by other cells remains to be deter-
mined (171).
In purified monocytes, GM-CSF induces phenotypic and
functional attributes of DCs (88, 89, 172). Similarly, purified
CD115+ MDPs respond to GM-CSF by differentiating into
CD11c+MHCII+ DCs (85) and GM-CSF deficiency leads to a
slight reduction of bone marrow MDPs and CDPs (164). How-
ever, GM-CSF is dispensable for the differentiation of lymphoid
tissue DCs (85, 173) and, therefore, it seemed likely that GM-
CSF would selectively regulate the differentiation of monocytes
into cells resembling DCs (23). This speculation also lead to the
hypothesis that monocytes cultured in the presence of GM-CSF
represent the counterpart of mo-DCs generated under conditions
of inflammation/infection in vivo (23). Surprisingly, GM-CSF
does not appear to control monocyte differentiation in vivo (90)
and thus, GM-CSF elicited monocyte-derived cells are unlikely
to be fully equivalent to inflammatory monocyte-derived cells.
Rather, GM-CSF influences the homeostasis of cDCs in a variety,
but not all, non-lymphoid tissues, most likely by promoting cell
survival (90). Importantly, GM-CSF deficiency leads to a greater
reduction of CD103+ cDCs than of CD11b+ cDCs (90). However,
the extent of cDC reduction in the absence of GM-CSF apparently
relates to the markers used for cell identification (90, 147, 164).
This is most likely because GM-CSF regulates certain phenotypic
as well as functional features of DCs, such as CD103 expression
(174) or their ability to cross-present antigen (90, 174, 175).
Therefore, the above-mentioned growth factors not only influence
lineage decisions but also impact on the functional regulation of
DCs, monocytes, and MØs. Elucidating the exact roles of FLT3L,
GM-CSF, and M-CSF in each cell type will help to decipher the
functional heterogeneity of MPs.
Cellular Barcoding
The biggest challenge for fate mapping is to trace the develop-
mental plasticity of individual cells. This can now be achieved
using “cellular barcoding,” in which progenitors are tagged in vitro
with semi-random, non-coding DNA sequences by transduction
using retro- or lentiviral vectors (Figure 2C) (81). Therefore,
the barcodes are heritable and by choosing conditions of low
transduction efficiency one can ensure that each cell receives only
a single barcode. Subsequently, barcode-labeled progenitors are
adoptively transferred in numbers low enough to minimize the
chance that two identically barcoded cells are transferred into
the same recipient (Figure 2C). After differentiation in vivo, cell
progeny are analyzed for their barcode repertoire using deep
sequencing or custom microarray. Since each barcode represents
an individual progenitor, the presence of the same barcode in
more than one cell type indicates that they were generated from
a single precursor (multi-potent or bi-potent, Figure 2C). On the
other hand, if a barcode is only found in one cell type, the progen-
itor generated only a single cell lineage (mono-potent, Figure 2C)
(81).
During maturation, HSCs are thought to progressively lose
their self-renewal ability and become increasingly limited in
their differentiation potential, ultimately giving rise to lineage-
restricted progenitors (55, 176). Lymphoid primed multi-potent
progenitors (LMPPs) are developmental intermediates down-
stream of HSCs that can give rise to various, but not all, cell lin-
eages and are thus consideredmulti-potent (55, 176). Surprisingly,
in barcoding experiments only a minority (3%) of single LMPPs
exhibits true multi-potency, defined as the ability to generate all
of the following cell lineages: B cells, DCs, and myeloid cells
(monocytes and neutrophils) (49). Rather, single LMPPs differ
drastically in terms of their cellular output: 10% of the progen-
itors contribute primarily to B cells, 10% primarily to myeloid
cells but about 50% of transferred LMPPs produce predominantly
DCs (49). The remaining fraction of progenitors exhibits bi-
potentiality to generate combinations of the examined cell lineages
(49). Therefore, LMPPs are multi-potent when analyzed as a pop-
ulation, however single cells exhibit unexpected lineage bias that
is imprinted early in development. Why the majority of LMPPs
is DC-committed (49), even though DCs constitute a minority
lineage compared to B cells, remains to be clarified, although it
is possible that some progenitors proliferate better than others or
have certain competitive advantages. A major lineage divergence
toward DCs seems to occur before or at the LMPP stage, as most
HSCs analyzed by the same method are multi-potent, although
even HSCs exhibit a degree of lineage bias (49, 177). Since CDPs
might arise directly from LMPPs without additional develop-
mental intermediates (79), these data infer that DCs diverge as
a developmental lineage distinct from other myeloid cells early
on (49).
This, again, questions the existence of a bi-potential MDP as
central intermediate in the development of DCs and monocytes.
Yet, it is noteworthy that even though DC-biased LMPPs are
fivefoldmore frequent than bi-potentmyeloid/DCLMPPs,mono-
potent and bi-potent progenitors contribute equally to the final
DC pool (49). Therefore, bi-potent progenitors seem to play a
significant part in generating DCs, potentially because they have a
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proliferative advantage. Resolving these issues will require further
refinement of the technique at hand. The differentiation potential
of progenitors may be influenced by cell isolation, processing
or in vitro manipulation (80) and virus-mediated transformation
might skew cell fate in an unforeseeable manner, as evidenced by
the fact that barcoded LMPPs cannot generate T cells (49, 81). This
also means that barcoding does not yet uncover the full potential
of single progenitors. The early lineage bias of HSCs and LMPPs
suggests that cell developmentmay follow amodel of graded com-
mitment rather than proceeding in a truly stepwise manner (178).
It will be interesting to determine, to what extent this process
is regulated by epigenetic modification and how inflammatory
processes might impact on lineage divergence. Future studies will
benefit from the development of models allowing for in vivo
barcoding of single cells but the labor-intensive quantification
and analysis of barcoding experiments makes it difficult to follow
populations in real time.
Genetic Lineage Tracing
Dynamic mapping of populations of distinct origin in vivo can be
achieved using genetic lineage tracing based on Cre-loxP technol-
ogy (Figure 2D) (80, 179). It relies on inducible reporter genes that
are placed under the control of constitutively active promoters,
such as the Rosa26 locus. The reporter is most commonly a fluo-
rescent protein that is preceded by a loxP-flanked STOP cassette
and, therefore, its expression is induced only after Cre recom-
binase (Cre) mediated excision of the stop codon (Figure 2D).
Since this form of labeling is genetic it is also heritable, meaning
that any cell expressing Cre will pass on the label to all progeny,
irrespective of continuous recombinase expression (Figure 2D).
Since the promoter driving the reporter gene is constitutively
active, labeling is irreversible and not affected by fluctuations in
gene expression (Figure 2D) (80).
By crossingmice expressing Cre under the control of theClec9a
locus to Rosa26-STOP-flox-enhanced-yellow fluorescent protein
(YFP) reporter mice (180), we have recently generated the first
genetic model to trace the progeny of DNGR-1+ CDPs and pre-
DCs (36). In these mice, YFP expression is restricted to DCs but is
not found inmonocytes orMØs even in inflammatory conditions,
as tested after intestinal inflammation or infection with L. mono-
cytogenes (36). Nonetheless, certain limitations need to be taken
into account. DNGR-1 is also expressed on CD8α+/CD103+
cDCs and to a lower extent on pDCs (36, 71, 181, 182) and,
therefore, in these populations labeling is not a strict indicator
of cell ontogeny. Further, labeling of CDP and pre-DC progeny
in mice heterozygous for Cre is incomplete, possibly due to a
delay in Cre protein synthesis and DNA recombination in rapidly
cycling progenitors (36). Consistently, penetrance of the YFP label
is increased in mice homozygous for Cre (36). The efficiency of
lineage tracing experiments in such cases or when Cre expression
is low may be improved by using alternate reporter constructs in
which the loxP sites are positioned closer together, thus facilitating
recombination (183).
Genetic lineage tracing does not require prior knowledge of
which markers are expressed by the output cells and, thus, enables
unbiased monitoring of cell ontogeny. Therefore, we were able to
identify CDP-derived cells in cell populations previously thought
to constitute monocytes/MØs based on the expression of sur-
face markers, such as CD64 (36). CD64+ CDP-derived cells do
not express Clec9a message and are especially frequent in kid-
neys, although the presence of few YFP+ cells in the CD64+
component of lung and small intestine indicates that atypical
CDP-derived cells also exist in other tissues (36). CD64+ kid-
ney DCs resemble yolk sac-derived F4/80hi tissue-resident MØs,
appear to lack Zbtb46 expression (37) and their affiliation as DCs
or MØs has been debated (184). We, therefore, used adoptive
transfer as additional method to confirm cell ontogeny. Surpris-
ingly, neither purified DNGR-1+ CDPs nor total bone marrow
generated F4/80hiCD64+ CDP progeny in kidneys 1week after
adoptive transfer into irradiated recipients (36). Since kidney
DCs reportedly have a slow turnover (185), it is possible that
CDPs had insufficient opportunity to reach their renal niche and
expand during short-term transfer experiments. Consistent with
this notion, F4/80hiCD64+ kidney leukocytes were efficiently
generated from bone marrow progenitors in long-term reconsti-
tution experiments (36). Therefore, our data strongly support a
CDP origin of CD64+ kidney leukocytes, despite their phenotypic
resemblance to monocytes or MØs (36). These data exemplify the
power of lineage tracing in following cell ontogeny in an unbiased
way, although it is possible that DNGR-1 is expressed on yet
unidentified developmental intermediates.
Addressing this possibility might require tamoxifen-inducible
Cre constructs that can be used to pulse label progenitor pop-
ulations (80). In the future, combinatorial approaches, such as
“split-Cre” fragments controlled by two different promoters (186)
or an intersection where Cre and the inducible reporter are driven
by two cell-specific promoters (187, 188) may be of benefit to
generate improvedmodels to lineage traceDCs. The identification
of CDP-derived cells with attributes of monocytes/MØs exem-
plifies the insufficiency of phenotypic properties, such as surface
markers, as means of accurate cell identification of MPs. It also
raises the question why cells of distinct ontogeny but overlapping
phenotype exist in the same tissue. Further elucidation of the
specific functions of MPs in immunity will benefit from lineage
tracing approaches that result in target cell deletion through the
use of inducible DTR or DT subunit modules (82, 112, 189, 190).
Conclusion
The studies discussed above have significantly advanced our
understanding of DC ontogeny but have also uncovered some
uncertainties (Figure 3). While the bone marrow origin of DCs
and monocytes is undisputed, the exact developmental inter-
mediates and branching points between HSCs and DC progen-
itors remain to be clarified. Current data indicate that lineage
imprinting toward DCs and monocytes may occur as early as
LMPPs, potentially through epigenetic modification (Figure 3).
This realization constitutes a major conceptual shift as it puts in
question the existence of a bi-potential MDP and the resulting
relatedness of DCs and monocytes. A definitive resolution of
this question requires increasingly refined methods to geneti-
cally trace single progenitors or select DC and monocyte lin-
eages. Nonetheless, it is clear that cDCs, pDCs, and monocytes
can be separated based on their descendance from committed
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FIGURE 3 | DCs develop as independent cell lineage. Although bone
marrow LMPPs are generally considered multi-potent, single LMPPs exhibit
a degree of lineage bias toward generating exclusively DCs or monocytes.
Such mono-potent LMPPs (single colored nuclei) may generate DC
progenitors and monocyte progenitors (cMoPs) directly without additional
developmental intermediates. In contrast, multi-potent LMPPs (tri-colored
nuclei) presumably give rise to DCs and monocytes via bi-potent MDPs and
CDPs. CDPs separate into pDC- and cDC-biased DC progenitors and can
be delineated from cMoPs based on the expression of surface markers,
including CD135, DNGR-1, Ly6C, and CD115 (as indicated in black). While
pDCs fully develop in the bone marrow, cDCs arise via pre-DCs, which
migrate through the blood stream to lymphoid and non-lymphoid tissues,
where they terminally differentiate into distinct cDC subsets. These
developmental processes are strongly driven by FLT3L and controlled by
several transcription factors (TF; indicated in blue). Monocytes also fully
differentiate in the bone marrow but upon entry into lymphoid and
non-lymphoid tissues and directed by environmental cues they can acquire
features of DCs or MØs. In contrast to DCs and monocytes, most
tissue-resident MØs arise from embryonic progenitors and are maintained by
self-renewal. Markers commonly used to distinguish pDCs, cDCs,
monocyte-derived cells, and MØs in mice are shown. (*) indicates that the
specified marker can be expressed on ontogenetically distinct MP subtypes
in some instances. (+/ ) indicates markers with heterogeneous or
tissue-dependent expression on the specified MP sublineage.
developmental intermediates (Figure 3). Their differentiation is
further driven by unique factors indicating that their develop-
mental paths are distinct (Figure 3). In stark contrast to pDCs,
cDCs, and monocytes, most tissue MØs arise from embryonic
progenitors and are predominantly maintained by self-renewal
into adulthood (Figure 3).
Taken together, these data unequivocally establish that DCs,
monocytes, and MØs develop as unique cellular entities and
although one could argue that most of this knowledge is derived
from mouse studies, developmental parallels have been observed
in other species (66–73). Despite these advances, we are at a
loss for a universal definition of DCs that is readily accessible to
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experts within and outside the field of MP biology. In light
of this recognition, it has been suggested to revise the current
nomenclature of MPs into a system that takes cell ontogeny
into account when defining subpopulations (6). Such system
would greatly aid our understanding of phagocyte biology as
it remains uncertain to what extent the cellular origin of DCs,
monocytes, and MØs determines the unique functionality of
these cells in immunity and/or tissue homeostasis. While global
profiling has revealed a role for the local tissue microenviron-
ment in shaping the transcriptional landscape of DCs, mono-
cytes, and MØs from different organs, certain gene signatures
and transcriptional features are set by ontogeny (167, 191–193).
Therefore, the full functional diversity of DCs, monocytes, and
MØs is likely shaped by both nature (ontogeny) and nurture
(the environment). Since ontogeny is immutable it provides a
more robust common denominator for cell definition that enables
deciphering cellular functions without assuming preconceived
functional or phenotypic relationships. DC classification based
on cell ancestry is a work in progress but its implementation
will ultimately yield a more robust and transparent way of cell
definition.
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